A Renewed Focus on the Pipeline


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 2130. Categories: , .

Product Description

Despite steady and significant increases in R&D spending, the number of new molecular entities (NMEs) and biologic license applications (BLAs) approved have been declining over recent years.
Current biopharma R&D operating models lack the flexibility required to effectively apply research capacity to meet shifting demand, according to executives at Deloitte. As a result, R&D is plagued by operational and governance constraints that drive costs up and limit choices at key stage gates, creating a variable and unsustainable flow of low-value products through the pipeline.
To rebuild sustainable pipelines with high-value products, R&D organizations must focus on actively balancing resources across the pipeline to consistently align capacity with demand and create choices that will differentiate products, according to recent studies by Deloitte. In many organizations this will require wholesale operational…

Success Rates

Enhancing the Pipeline: A Company by Company Approach
Global Pharmaceutical Market R&D Impact
Clinical Trials Grow in ­Complexity

John Arrowsmith, Ph.D. Scientific Director, Thomson Reuters, which delivers information to decision makers in the
financial, legal, tax and accounting, healthcare, science, and media markets. For more information, visit
John Blakeley. Executive VP, ERT, a global provider of technology and services to the pharmaceutical, biotechnology, and medical-device industries. For more information, visit
James A. Datin. Executive VP and Managing Director, Life Sciences Group, Safeguard Scientifics Inc., which provides growth capital for life-sciences and technology companies in the molecular and point-of-care diagnostics, medical devices, regenerative medicine and specialty pharmaceuticals, and technology companies. For more information, visit
Doug Fambrough. CEO, Dicerna Pharmaceuticals, a private, venture-backed, second generation RNA interference (RNAi) company developing novel therapeutic agents in multiple therapeutic areas. For more information, visit
Rick Heinick. Senior Partner and head of the M&A practice at Schaffer Consulting, where he advises CEOs and their teams on M&A integration and transformational change. For more information, visit
Nicholas Landekic. President and CEO, PolyMedix Inc., which is developing novel, first-in-class therapies for serious, life-threatening, acute disorders. For more ­information, visit
Michael Naimoli. Worldwide Managing Director, Microsoft Corp., which is committed to improving health around the world through software innovation. For more information, visit
Sanjeev Wadhwa. Partner, Director Life Sciences R&D, Computer Sciences Corp., which provides solutions that improve the way physicians deliver services, experts conduct breakthrough medical research, and institutions provide coverage. For more information, visit
Paul Chew, M.D. Senior VP, U.S. Chief Medical Officer/Chief Scientific Officer, Sanofi-Aventis US, a global pharmaceutical company that discovers, develops, and ­distributes therapeutic solutions to improve the lives of everyone. For more information, visit
Mark Fishman. President, Novartis ­Institutes for BioMedical Research (NIBR), the global pharmaceutical research ­organization for Novartis committed to ­discovering innovative medicines that treat disease and improve human health.
For more information, visit
Jean-Jacques Garaud. Global Head of Pharma Research and Early Development (pRED), Roche, which addresses unmet medical needs from early detection and prevention of diseases to diagnosis, ­treatment, and treatment monitoring. For more information, visit
Glenn J. Gormley, M.D., Ph.D. Chief Science Officer, Co-Head, Research & Development, Daiichi Sankyo; Global Head of Development, President, Daiichi Sankyo ­Pharma Development (DSPD), a member of the Daiichi Sankyo Group, which is dedicated to the creation and supply of pharmaceutical products to address the unmet medical needs of patients in both mature and emerging markets. For more information, visit
Jane H. Hollingsworth. CEO, NuPathe, a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including ­neurological and psychiatric disorders. For more information, visit
Robert T. McNally, Ph.D. President and CEO, GeoVax, a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immuno­deficiency Virus – AIDS) and other ­infectious agents. For more information, visit
Claire Thom, Pharm.D. Senior VP, ­Portfolio ­Management, Millennium: The Takeda Oncology Company, which is focused exclusively in oncology to improve the treatment of cancer around the world. For more information, visit
Kleanthis Xanthopoulos, Ph.D. ­President and CEO, Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of a new class of high-impact medicines based on microRNAs. For more information, visit ­